HK1030431A1 - Fusion proteins comprising hiv-1 tat and/or nef proteins - Google Patents

Fusion proteins comprising hiv-1 tat and/or nef proteins

Info

Publication number
HK1030431A1
HK1030431A1 HK00108429A HK00108429A HK1030431A1 HK 1030431 A1 HK1030431 A1 HK 1030431A1 HK 00108429 A HK00108429 A HK 00108429A HK 00108429 A HK00108429 A HK 00108429A HK 1030431 A1 HK1030431 A1 HK 1030431A1
Authority
HK
Hong Kong
Prior art keywords
proteins
tat
hiv
nef
fusion proteins
Prior art date
Application number
HK00108429A
Other languages
English (en)
Inventor
Claudine Bruck
Stephane Andre Georges Godart
Martine Marchand
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10819735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1030431(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of HK1030431A1 publication Critical patent/HK1030431A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK00108429A 1997-09-26 2000-12-27 Fusion proteins comprising hiv-1 tat and/or nef proteins HK1030431A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9720585.0A GB9720585D0 (en) 1997-09-26 1997-09-26 Vaccine
PCT/EP1998/006040 WO1999016884A1 (en) 1997-09-26 1998-09-17 Fusion proteins comprising hiv-1 tat and/or nef proteins

Publications (1)

Publication Number Publication Date
HK1030431A1 true HK1030431A1 (en) 2001-05-04

Family

ID=10819735

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00108429A HK1030431A1 (en) 1997-09-26 2000-12-27 Fusion proteins comprising hiv-1 tat and/or nef proteins

Country Status (28)

Country Link
EP (1) EP1015596B2 (xx)
JP (2) JP2001518300A (xx)
KR (1) KR100554487B1 (xx)
CN (1) CN1188519C (xx)
AR (2) AR017147A1 (xx)
AT (1) ATE338128T1 (xx)
AU (1) AU746564B2 (xx)
BR (1) BR9812547A (xx)
CA (1) CA2305013C (xx)
CO (1) CO4810339A1 (xx)
CZ (1) CZ302878B6 (xx)
DE (1) DE69835756T3 (xx)
DK (1) DK1015596T4 (xx)
ES (1) ES2272012T5 (xx)
GB (1) GB9720585D0 (xx)
HK (1) HK1030431A1 (xx)
HU (1) HUP0004896A3 (xx)
IL (1) IL135102A0 (xx)
NO (2) NO328824B1 (xx)
NZ (1) NZ503482A (xx)
PL (1) PL195243B1 (xx)
PT (1) PT1015596E (xx)
SA (1) SA98190877B1 (xx)
SI (1) SI1015596T2 (xx)
TR (1) TR200000864T2 (xx)
TW (1) TW499436B (xx)
WO (1) WO1999016884A1 (xx)
ZA (1) ZA988789B (xx)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
JP2002537354A (ja) * 1999-02-25 2002-11-05 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ペプチド、及びＨ．ｉｎｆｌｕｅｎｚａｅのプロテインＤ由来の担体を含む免疫原
AU4342900A (en) * 1999-04-12 2000-11-14 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
ATE306938T1 (de) * 1999-06-29 2005-11-15 Glaxosmithkline Biolog Sa Verwendung von cpg als adjuvans für hivimpstoff
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
PL211762B1 (pl) * 2000-01-31 2012-06-29 Smithkline Beecham Biolog Zastosowanie białka fuzyjnego zawierającego białka HIV Tat i HIV Nef lub polinukleotyd kodujący takie białko, białka lub polinukleotydu HIV gp120, białka lub polinukleotydu SIV Nef, adiuwanta indukującego TH1 zawierającego monofosforylolipid A lub jego pochodną i adiuwanta saponinowego oraz kompozycja szczepionki
WO2006033665A1 (en) 2004-03-16 2006-03-30 Inist Inc. Tat-based vaccine compositions and methods of making and using same
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
NZ532383A (en) 2001-11-21 2007-03-30 Univ Pennsylvania Pan-7 simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
KR100466382B1 (ko) * 2002-01-08 2005-01-14 주식회사 엘지생명과학 인간 면역 결핍 바이러스-1, -2 타입의 단백질이 융합된 재조합 콤보 단백질, 이의 생산방법, 이를 포함하는 벡터, 형질전환된 대장균 및 진단키트
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DK1506223T3 (da) 2002-05-16 2006-04-10 Bavarian Nordic As Fusionsprotein af regulatoriske/accessoriske HIV-proteiner
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0507003D0 (en) * 2005-04-06 2005-05-11 Molmed Spa Therapeutic
IN2014DN06624A (xx) 2005-10-18 2015-07-10 Univ Colorado
BRPI0819774A2 (pt) 2007-11-28 2014-10-14 Univ Pennsylvania Subfamília c de adenovírus sadv-40, -31 e -34 de símio e seus usos
DK2220241T3 (en) 2007-11-28 2017-01-09 Univ Pennsylvania Adenovirus comprising a simian adenovirus E-SAdV-39-capsidhexonprotein and uses thereof
JP5661476B2 (ja) 2008-03-04 2015-01-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
CA2723114C (en) 2008-05-16 2018-02-27 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
CN102083970B (zh) 2008-07-21 2014-10-22 泰加生物工艺学公司 分化无核细胞及其制备方法
DK2966084T3 (en) 2008-08-28 2018-08-06 Taiga Biotechnologies Inc MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC
EP2350269B1 (en) 2008-10-31 2015-09-09 The Trustees Of The University Of Pennsylvania Simian adenoviruses with sadv-46 hexon capsid proteins and uses thereof
CA2755897C (en) 2009-03-23 2020-01-28 Nanirx, Inc. Treatment of cancers with immunostimulatory hiv tat derivative polypeptides
US8846031B2 (en) 2009-05-29 2014-09-30 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
EP2643465B1 (en) 2010-11-23 2016-05-11 The Trustees Of The University Of Pennsylvania Subfamily e simian adenovirus a1321 and uses thereof
US9110059B2 (en) * 2011-03-15 2015-08-18 Industry-Academic Cooperation Foundation, Yonsei University Bio-pin
BR112014028684A2 (pt) 2012-05-18 2017-07-25 Univ Pennsylvania subfamília e adenovírus de símio a1302, a1320, a1331 e a1337 e usos dos mesmos
WO2014012090A1 (en) * 2012-07-13 2014-01-16 The Broad Institute, Inc. Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof
US9789135B2 (en) 2012-07-20 2017-10-17 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9663556B2 (en) 2013-10-04 2017-05-30 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV tat derivative polypeptides
CA2947614C (en) 2014-05-13 2023-10-03 The Trustees Of The University Of Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof
CN107708671B (zh) * 2015-04-16 2020-12-04 纽约州立大学研究基金会 包含钴卟啉-磷脂缀合物和聚组氨酸标签的纳米结构
US11207421B2 (en) 2015-04-16 2021-12-28 The Research Foundation For The State University Of New York Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
KR20190092472A (ko) 2016-12-02 2019-08-07 타이가 바이오테크놀로지스, 인코포레이티드 나노입자 제제
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
MX2023012643A (es) 2021-04-27 2024-01-05 Generation Bio Co Vectores de adn no virales que expresan anticuerpos terapéuticos y usos de estos.
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9003010D0 (en) * 1990-02-09 1990-04-04 Glaxo Group Ltd Gene expression in yeast cells
JPH07502646A (ja) * 1991-10-21 1995-03-23 メディミューン，インコーポレーテッド リポタンパク質の分泌シグナルをコード化するｄｎａを含む細菌発現ベクター
ES2123062T3 (es) * 1992-08-21 1999-01-01 Biogen Inc Polipeptidos de transporte derivados de la proteina tat.
NZ262582A (en) * 1993-01-26 1997-10-24 David B Weiner Compositions and methods for delivery of genetic material
EP0814834B2 (fr) * 1995-03-08 2009-03-18 Neovacs Immunogenes denues de toxicite derivant d'une proteine de regulation retrovirale, anticorps diriges contre ces immunogenes, procede pour leur preparation et compositions pharmaceutiques les renfermant
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
TR200000864T2 (tr) 2000-08-21
ATE338128T1 (de) 2006-09-15
ES2272012T5 (es) 2010-07-06
GB9720585D0 (en) 1997-11-26
DE69835756D1 (de) 2006-10-12
DK1015596T4 (da) 2010-07-12
SA98190877B1 (ar) 2006-09-10
KR20010024287A (ko) 2001-03-26
DE69835756T3 (de) 2010-09-30
JP2009213492A (ja) 2009-09-24
SI1015596T1 (sl) 2007-02-28
SI1015596T2 (sl) 2010-07-30
HUP0004896A3 (en) 2003-05-28
CN1188519C (zh) 2005-02-09
HUP0004896A1 (hu) 2001-04-28
CN1279718A (zh) 2001-01-10
CZ302878B6 (cs) 2012-01-04
EP1015596B1 (en) 2006-08-30
AU1025599A (en) 1999-04-23
NO20001508D0 (no) 2000-03-23
PT1015596E (pt) 2006-12-29
DK1015596T3 (da) 2007-01-02
CZ20001091A3 (cs) 2000-09-13
PL195243B1 (pl) 2007-08-31
DE69835756T2 (de) 2007-09-13
EP1015596A1 (en) 2000-07-05
CA2305013A1 (en) 1999-04-08
NO20076467L (no) 2000-05-18
AR080331A2 (es) 2012-03-28
EP1015596B2 (en) 2010-04-14
NZ503482A (en) 2001-09-28
WO1999016884A1 (en) 1999-04-08
NO20001508L (no) 2000-05-18
IL135102A0 (en) 2001-05-20
TW499436B (en) 2002-08-21
KR100554487B1 (ko) 2006-03-03
PL339432A1 (en) 2000-12-18
CA2305013C (en) 2008-04-08
AU746564B2 (en) 2002-05-02
NO328824B1 (no) 2010-05-25
CO4810339A1 (es) 1999-06-30
ZA988789B (en) 2000-03-29
BR9812547A (pt) 2000-07-25
AR017147A1 (es) 2001-08-22
JP2001518300A (ja) 2001-10-16
ES2272012T3 (es) 2007-04-16

Similar Documents

Publication Publication Date Title
IL135102A0 (en) Fusion proteins comprising hiv-1 tat and/or nef proteins
HUP0200414A2 (en) Interferon-betha fusion proteins and uses
GB9718609D0 (en) Fusion protein
AU8828598A (en) Retrovirus and viral vectors
IS4814A (is) Tilbúin HIV gen
ZA975889B (en) HIV envelope polypeptides and vaccine.
EP0626450A3 (en) Fusion proteins containing the enzyme ubiquitin conjugate (E2).
IL122898A0 (en) Allergan -XCD32 fusion proteins
AU9798398A (en) Gfp-annexin fusion proteins
CZ2000522A3 (cs) Farmaceutický prostředek na bázi piperidinalkanolového antihistaminika a použití
GB2336844B (en) Anti-hiv peptides and proteins
SI1121382T1 (sl) Fuzijski proteini interferona-beta in uporabe
AU2002300390A1 (en) Fusion proteins comprising HIV-1 TAT and/or NEF proteins
EP1037963A4 (en) X-RAY CRYSTAL COMPRISING HIV-1 GP120
AU7960298A (en) Two human membrane fusion proteins
GB9713150D0 (en) Fusion proteins
BR7501787U (pt) Faca soldada
IL120392A0 (en) Novel PKA-binding proteins and uses thereof
IL120413A0 (en) Novel PKA-binding proteins and uses thereof
GB9812756D0 (en) Assay procedure for identifying inhibitors of the nuclease-inhibitory function of the human immunodeficiency virus tat protein
BR7501788U (pt) Faca calçada por brasagem
GB9722003D0 (en) Proteins
GB9722727D0 (en) Proteins
GB9707822D0 (en) Proteins
GB9703104D0 (en) Proteins

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150917